Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Fountain Therapeutics Inc.

Headquarters: South San Francisco, CA, United States of America
Year Founded: 2018
Status: Private

BioCentury | Dec 22, 2022
Management Tracks

Genentech bolsters marketing team

Plus: Greene becomes chief investment officer at Hevolution, and updates from Aerami and Curate
BioCentury | Jan 19, 2022
Management Tracks

Interim no more: Zhang assumes Overland’s CEO post; Maraganore, Ho join as advisers

Plus: Merck KGaA strategy, R&D execs; and updates from CureVac, Exo, Krystal and more
BioCentury | Nov 19, 2021
Finance

Nov. 18 Quick Takes: RA’s Avilar raises $60M seed for protein degradation tech

Sanofi invests in Owkin, plus Treadwell, Protego, BAKX, Fountain, Takeda-Denali
BioCentury | Apr 29, 2021
Management Tracks

Cytovia names Frankel CMO; plus Bantam, GreenLight, Edgewise, CohBar and more

CAR NK cell therapy and antibody play Cytovia Therapeutics Inc. hired Stanley Frankel as CMO. Frankel was SVP of cellular therapy development at Bristol Myers Squibb Co. (NYSE:BMY). Bantam
BioCentury | Jul 22, 2020
Emerging Company Profile

Deep Longevity: Insilico spinout clocks biological age

Deep Longevity’s biomarkers could be used to measure the efficacy of anti-aging therapeutics
BioCentury | Jul 16, 2020
Emerging Company Profile

Fountain Therapeutics: an AI-based platform to reverse cellular aging

Fountain’s AI-driven platform measures cellular age as the basis for anti-aging drug screens
Items per page:
1 - 6 of 6